Dr. Martin delivers a critical and detailed overview of the U.S. regulatory landscape surrounding stem cells, emphasizing that using the term “stem cells” in clinical practice is scientifically inaccurate and legally risky. He explains that current compliant use involves human cell and tissue products (HCTPs) like Wharton's Jelly, which are structural allografts meant to supplement local cartilage defects—not regenerate tissue or treat systemic diseases like osteoarthritis, which would constitute unapproved drug claims.